

PRESS RELEASE

Hematopoietic stem cell transplantation in Europe 2014: more than 40,000 transplants annually

Barcelona, 16 March 2016 – The European Society for Blood and Marrow Transplantation (EBMT) annual survey continues to provide valuable and up-to-date information on use of hematopoietic stem cell transplantation (HSCT) throughout Europe. It not only reflects current practice but also provides essential material for health care planning and health policy makers. The results of the Transplant Activity Survey have been published recently in *Bone Marrow Transplantation*, the official journal of the EBMT.

HSCT is an established procedure for many acquired and congenital disorders of the hematopoietic system, including disorders of the immune system, and as enzyme replacement in metabolic disorders.

In 1990, the EBMT introduced the Activity Survey, a novel tool for assessing the real picture of HSCT in Europe. On an annual basis, all EBMT members and affiliated teams report their number of transplant patients by indication, donor type and stem cell source.

The Activity Survey has evolved into a mandatory self-reporting system and it forms an integral part of the international quality assurance programme JACIE. A second survey on cellular therapies and tissue engineering introduced in 2008 provides an overview of the latest developments in the field of non-HSCT cellular therapies. This coincides with the recent interest of the World Health Organization (WHO) in cell and tissue transplants, and further stresses the need for adequate and timely information. The analysis of the survey data spanning over 20 years has shown a continued and constant increase in the annual numbers of HSCT and transplant rates (number of HSCT per 10 million inhabitants) for both allogeneic and autologous HSCT.

This year report is based on the 2014 survey data. In addition to transplant rates and indications, this report focuses on the use of donors other than HLA identical siblings and matched unrelated donors for allogeneic HSCT.

A record number of 40,829 HSCT in 36,469 patients were reported by 656 centers in 47 countries to the 2014 survey.

For more information, please read the original article:

<http://www.nature.com/bmt/journal/vaop/ncurrent/pdf/bmt201620a.pdf>

*** END ***

About the European society for Blood and Marrow Transplantation (EBMT)

The EBMT is a not-for-profit medical and scientific organisation established in 1974. It is dedicated to fighting life-threatening blood cancers and diseases and improving patients' lives. The EBMT Members - more than 4,000 physicians, nurses, scientists and other healthcare professionals - participate in a unique collaborative network of peers involved in haematopoietic stem cell transplantation (HSCT) and cellular therapy research. The membership encompasses at least 600 centres who are performing or are involved in HSCT in more than 60 countries. The EBMT holds a central role in performing co-operative studies and disseminating state-of-the-art knowledge aimed at increasing survival rates and enhancing the quality of life of patients with life-threatening blood cancers and diseases. For further information about the EBMT, please visit the website: www.ebmt.org and follow us on Twitter: @TheEBMT

For any further information about the Transplant Activity Survey, please contact:

Helen Baldomero - Activity Survey Coordinator: helen.baldomero@usb.ch

Jakob R. Passweg - Activity survey Clinical Advisor: jakob.passweg@usb.ch

Press contact

EBMT - Mélanie Chaboissier

Phone : +34 93 453 8570 – E-mail : melanie.chaboissier@ebmt.org